Key result
Vildagliptin improves central SBP and augmentation index in a single hypertensive diabetic patient.
Why the study?
Pharmacotherapy for type 2 diabetes should improve blood glucose control and provide beneficial glucose-independent cardiovascular effects, with central SBP being important for cardiovascular risk assessment.
Does vildagliptin improve central systolic blood pressure and arterial stiffness in a patient with hypertension and type 2 diabetes mellitus?
Case Report (n=1)
Does vildagliptin improve central systolic blood pressure and arterial stiffness in a patient with hypertension and type 2 diabetes mellitus?
Vildagliptin may improve arterial stiffness parameters (central SBP and AIx) in patients with hypertension and type 2 diabetes, suggesting a glucose-independent cardiovascular benefit.
May suggest vascular benefit in one T2DM-hypertension case; hypothesis-generating and should not change practice.
Hypertension and type 2 diabetes mellitus (DM) are among the main risk factors for the development of cardiovascular disease. Pharmacotherapy for DM should not only improve blood glucose control, but also provide beneficial glucose-independent cardiovascular effects. The central systolic blood pressure (SBP) has become more important than the brachial SBP in the assessment of cardiovascular risk.This case report describes the effect of vildagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, on the central SBP in a 54-year-old woman with hypertension and DM. She was submitted to applanation tonometry (AT) before and after vildagliptin association. AT of the radial artery is a non-invasive method that indirectly assesses arterial stiffness by calculating the central SBP and the augmentation index (AIx).After 3 months of follow-up using vildagliptin, central SBP and AIx were improved. Moreover, she presented better glycemic control.This case suggests an effect of DPP-4 inhibitor on arterial stiffness parameter (central SBP) in a hypertensive and diabetic patient, which shows a glucose-independent beneficial cardiovascular effect of this group of drugs.
No takes yet. Share an insight, caveat, or question.
Cosenso‐Martin et al. (2015) conducted a case report in Hypertension and type 2 diabetes mellitus (n=1). Vildagliptin vs. Baseline was evaluated on Central systolic blood pressure (SBP) and augmentation index (AIx). Vildagliptin improved central systolic blood pressure and augmentation index after 3 months of follow-up in a 54-year-old woman with hypertension and type 2 diabetes.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: